合成肽 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-20. Numbers and descriptions here follow the published literature rather than marketing material.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Free base form |
| Molecular mass | Approximately 4813 Da | Calculated from the sequence |
| Amino acid residues | 39 | GIP-derived backbone |
| Receptor targets | GIP and GLP-1 | Dual agonist |
| Circulating half-life | About 5 days | Supports weekly administration |
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
=== Further clinical studies === Ga-NODAGA-JR11 had entered further clinical studies as an imaging agent, while and Lu-DOTA-JR11 had similar research done as a therapeutic agent, as JR11 has a high binding affinity for ssrt2 subtype receptors which are highly expressed on the surface of tumor cells. Gallium-containing agonists had already been established as an imaging agent. Lutetium-containing agonists were used as a therapeutic agent in peptide receptor radionuclide therapy, due to the lower energy electrons emitted, and γ-emission causing easier dose adjustment to patient characteristics to avoid renal damage. The NODAGA chelator was used over DOTA in Gallium antagonists due to higher binding affinity, while no Lu-NODAGA compounds were developed due to established usage of Lu-DOTA derivative agonist drugs, and poor uptake compared to DOTA, which is reverse that of the gallium-containing antagonists.
Moscow offers vehicle sharing options that are sponsored by the local government. Several car-sharing companies are responsible for providing cars to the population. To drive one of these cars, a user must book it through the app (application software) of the owning company. In 2018, Mayor Sergey Sobyanin said that Moscow's car-sharing system had become Europe's largest fleet. Every day, about 25,000 people used this service. By the end of that year, Moscow carsharing had become the world's second largest, with 16,500 vehicles available. Another sharing system is bike sharing (Moscow's Velobike system), with a fleet of 3000 traditional and electric bicycles. The Delisamokat is a new sharing service providing electric scooters.
== Further reading == Kielley WW, Bradley LB (1954). "Glutathione thiolesterase". J. Biol. Chem. 206 (1): 327–33. doi:10.1016/S0021-9258(18)71321-5. PMID 13130552. Murata, Kousaku; Sato, Nobuyuki; Rhee, Hae-ik; Watanabe, Kunihiko; Kimura, Akira (1987). "Purification and Characterization of Glutathione Thiol Esterase from Saccharomyces cerevisiae". Agricultural and Biological Chemistry. 51 (7): 1901–1907. doi:10.1080/00021369.1987.10868321. Uotila, Lasse (1979). "Glutathione thiol esterases of human red blood cells". Biochimica et Biophysica Acta (BBA) - Protein Structure. 580 (2): 277–288. doi:10.1016/0005-2795(79)90140-5. PMID 93000.
==== MeSH E05.200.500 – cytological techniques ==== MeSH E05.200.500.105 – autoradiography MeSH E05.200.500.195 – cell count MeSH E05.200.500.195.107 – blood cell count MeSH E05.200.500.195.107.330 – erythrocyte count MeSH E05.200.500.195.107.330.725 – reticulocyte count MeSH E05.200.500.195.107.595 – leukocyte count MeSH E05.200.500.195.107.595.500 – lymphocyte count MeSH E05.200.500.195.107.595.500.150 – cd4 lymphocyte count MeSH E05.200.500.195.107.595.500.150.160 – cd4-cd8 ratio MeSH E05.200.500.195.107.740 – platelet count MeSH E05.200.500.195.870 – sperm count MeSH E05.200.500.251 – cell fractionation MeSH E05.200.500.307 – cell fusion MeSH E05.200.500.363 – cell separation MeSH E05.200.500.363.285 – cytapheresis MeSH E05.200.500.363.285.570 – leukapheresis MeSH E05.200.500.363.285.790 – plateletpheresis MeSH E05.200.500.363.400 – immunomagnetic separation MeSH E05.200.500.363.540 – leukocyte reduction procedures MeSH E05.200.500.383 – colony-forming units assay MeSH E05.200.500.383.910 – tumor stem cell assay MeSH E05.200.500.385 – cytogenetic analysis MeSH E05.200.500.385.130 – chromosome banding MeSH E05.200.500.385.500 – mitotic index MeSH E05.200.500.386 – cytophotometry MeSH E05.200.500.386.350 – flow cytometry MeSH E05.200.500.386.400 – image cytometry MeSH E05.200.500.386.400.500 – laser scanning cytometry MeSH E05.200.500.387 – diffusion chambers, culture MeSH E05.200.500.388 – drug screening assays, antitumor MeSH E05.200.500.388.930 – tumor stem cell assay MeSH E05.200.500.410 – electroporation MeSH E05.200.500.607 – histocytochemistry MeSH E05.200.500.607.512 – immunohistochemistry MeSH E05.200.500.607.790 – periodic acid-schiff reaction MeSH E05.200.500.607.810 – prussian blue reaction MeSH E05.200.500.620 – histocytological preparation techniques MeSH E05.200.500.620.530 – microtomy MeSH E05.200.500.620.530.160 – cryoultramicrotomy MeSH E05.200.500.620.530.160.260 – frozen sections MeSH E05.200.500.620.620 – replica techniques MeSH E05.200.500.620.620.150 – corrosion casting MeSH E05.200.500.620.620.260 – freeze fracturing MeSH E05.200.500.620.620.260.400 – freeze etching MeSH E05.200.500.620.670 – staining and labeling MeSH E05.200.500.620.670.130 – chromosome banding MeSH E05.200.500.620.670.325 – in situ hybridization MeSH E05.200.500.620.670.325.350 – in situ hybridization, fluorescence MeSH E05.200.500.620.670.325.350.125 – chromosome painting MeSH E05.200.500.620.670.325.680 – primed in situ labeling MeSH E05.200.500.620.670.520 – negative staining MeSH E05.200.500.620.670.620 – periodic acid-schiff reaction MeSH E05.200.500.620.670.660 – prussian blue reaction MeSH E05.200.500.620.670.770 – shadowing (histology) MeSH E05.200.500.620.670.780 – silver staining MeSH E05.200.500.620.720 – tissue embedding MeSH E05.200.500.620.720.610 – paraffin embedding MeSH E05.200.500.620.720.640 – plastic embedding MeSH E05.200.500.620.760 – tissue preservation MeSH E05.200.500.620.760.160 – cryopreservation MeSH E05.200.500.620.760.160.260 – freeze drying MeSH E05.200.500.620.760.160.260.270 – freeze substitution MeSH E05.200.500.620.760.720 – tissue fixation MeSH E05.200.500.695 – karyometry MeSH E05.200.500.800 – patch-clamp techniques
Sources: en.wikipedia.org
== Progression == Reports of a fire at the warehouse first began shortly after 2:30 p.m. June 17, 2026, a 491,000-square-foot commercial cold storage facility operated by Lineage Logistics at 1400 S. Los Palos St. About two hours later, a large black smoke cloud erupted over the warehouse, which could be seen throughout the city, even days after the fire had started. A state of emergency was declared three days later on June 20 by Mayor Bass.
Beriglobin P, human hepatitis A immunoglobulin, liquid 16% solution for intramuscular injection Berirab P, human rabies immunoglobulin, liquid 16% solution for intramuscular injection Carimune NF, Sandoglobulin, Sanglopor human normal immunoglobulin, freeze-dried formulations for intravenous administration Cytogam, human cytomegalovirus immunoglobulin. Liquid immunoglobulin containing a standardized amount of antibody to cytomegalovirus. Hepatitis B Immunoglobulin P Behring, human hepatitis B immunoglobulin, liquid 16% solution for intramuscular injection Hizentra, Human normal immunoglobulin. Liquid 20% immunoglobulin solution, ready-to-use for subcutaneous administration Privigen, human polyvalent immunoglobulin, liquid 10% solution for intravenous injection Rhesogamma P, human anti-D immunoglobulin. Prefilled syringes of highly purified anti-Rhesus factor D IgG for intravenous administration and intramuscular injection. Rhophylac human anti-D immunoglobulin. Prefilled syringes of highly purified anti-Rhesus factor D IgG for intravenous administration and intramuscular injection. Sandoglobulin NF Liquid, Redimune, Redimune NF Liquid, human normal immunoglobulin, liquid 12% solution for intravenous administration Tetagam P, human tetanus immunoglobulin, liquid 16% solution for intramuscular injection Varicellon P, human varicella immunoglobulin, liquid 16% solution for intramuscular injection Vivaglobin, human normal immunoglobulin, liquid 16% solution for subcutaneous administration Coagulation/Bleeding Disorders:
Anahuasca (ayahuasca analogue or variants). A term usually used to refer to the ayahuasca produced with other plant species as sources of DMT (e.g., Mimosa hostilis) or β-carbolines (e.g., Peganum harmala). Pharmahuasca (pharmaceutical ayahuasca). This indicates the pills produced from freebase DMT, synthetic harmaline, MAOI medications (such as moclobemide) and other isolated or purified compounds or extracts.
Sources: en.wikipedia.org
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.
A fatty diacid side chain promotes binding to albumin, which delays clearance from circulation. The half-life of roughly five days makes a weekly schedule practical.
No. It is a synthetic peptide whose backbone is based on the natural incretin hormone GIP. Non-natural residues and the lipid side chain were engineered to improve stability and duration of action.
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.